. 2022 Apr 27;36(3):341–358. doi: 10.1007/s40259-022-00530-0

Table 2.

Calcitonin gene-related peptide (CGRP) small molecule antagonists (gepants)

Name	Target	Route	T_1/2	T_max	Dose	Frequency
Ubrogepant (MK-1602)	CGRP receptor	PO	5–7 h	1.5 h	50 mg 100 mg	PRN^a
Rimegepant (BMS-927711)	CGRP receptor	PO	11 h	1.5 h	75 mg	PRN^a QoD^b
Atogepant (MK-8031)	CGRP receptor	PO	11 h	2 h	10 mg 30 mg 60 mg	QD^b

Name

Target

Route

T_1/2

T_max

Dose

Frequency

Ubrogepant

(MK-1602)

CGRP receptor

5–7 h

1.5 h

50 mg

100 mg

PRN^a

Rimegepant

(BMS-927711)

CGRP receptor

11 h

1.5 h

75 mg

PRN^a

QoD^b

Atogepant

(MK-8031)

CGRP receptor

11 h

2 h

10 mg

30 mg

60 mg

QD^b

PO oral, QoD every other day, T_1/2 half-life, T_max time to peak drug concentration, QD daily, PRN as needed

^aAs an abortive agent

^bAs a preventive agent